Logistic regression models to investigate associations with repair (n=17)
| OR | 95% CI | P value | |
| Duration of previous remission | 1.005 | 0.802 to 1.26 | 0.963 |
| Symptom duration at baseline (weeks) | 0.972 | 0.95 to 1.00 | 0.051 |
| Mean DAS from month 3 to time of repair | 0.82 | 0.40 to 1.63 | 0.566 |
| Previous prednisone | 1.09 | 0.385 to 3.09 | 0.871 |
| Previous infliximab | 0.599 | 0.206 to 1.74 | 0.347 |
| ACPA | 1.51 | 0.413 to 5.53 | 0.533 |
| Gender | 1.13 | 0.401 to 3.16 | 0.822 |
| Baseline age | 1.01 | 0.975 to 1.05 | 0.548 |
| BMI | 1.03 | 1.00 to 1.05 | 0.056 |
| Randomisation arm | |||
| Sequential monotherapy | Ref | – | – |
| Step-up combination therapy | 0.798 | 0.231 to 2.75 | 0.721 |
| Initial combination with prednisone | 0.597 | 0.158 to 2.26 | 0.448 |
| Initial combination with infliximab | 0.147 | 0.0173 to 1.25 | 0.080 |
All models were adjusted for mean Sharp/van der Heijde score until repair.
ACPA, anticitrullinated peptide antibody; DAS, disease activity score.